Development and characterization of in situ gel system for nasal insulin delivery

被引:52
作者
Agrawal, A. K. [2 ]
Gupta, P. N. [1 ]
Khanna, A. [2 ]
Sharma, R. K. [2 ]
Chandrawanshi, H. K. [2 ]
Gupta, N. [3 ]
Patil, U. K. [2 ]
Yadav, S. K. [2 ]
机构
[1] Queens Univ Belfast, Sch Pharm, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland
[2] VNS Inst Pharm, Drug & Vaccine Delivery Res Lab, Bhopal, MP, India
[3] Sagar Inst Pharmaceut Sci, Sagar, MP, India
来源
PHARMAZIE | 2010年 / 65卷 / 03期
关键词
PVA/CHITOSAN-BLENDED HYDROGELS; CHITOSAN NANOPARTICLES; ALCOHOL) HYDROGEL; BIOAVAILABILITY; ABSORPTION; RELEASE; MICROSPHERES; FORMULATIONS; ENHANCEMENT; POLYMERS;
D O I
10.1691/ph.2010.9188
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
The objective of the present study was to develop a thermosensitive in situ gel system based on chitosan and poly vinyl alcohol (PVA) for nasal delivery of insulin The hydrogel was prepared by mixing chitosan and PVA. The concentration of the components was optimized during formulation development The prepared hydrogel was characterized for gelation temperature, gelation time, viscosity changes, degree of swelling, in vitro release and in vivo hypoglycemic effect. The prepared hydrogel was liquid at room temperature while underwent thermal transition from solution below or at room temperature to non-flowing hydrogel when incubated at 37 C for approximately 12 minutes with increased viscosity. The in vitro release of insulin from gel network was observed spectrophotometrically which was good enough to maintain blood glucose level for six hour. Furthermore, the formulation when evaluated for their in vivo hypoglycemic effect, demonstrated its ability to reduce glucose level. The observed in vitro and in vivo results indicate that the proposed thermosensitive in situ gelling system has substantial potential as nasal delivery system for insulin
引用
收藏
页码:188 / 193
页数:6
相关论文
共 43 条
[1]
Drug release from pH-response polyvinylacetal diethylaminoacetate hydrogel, and application to nasal delivery [J].
Aikawa, K ;
Mitsutake, N ;
Uda, H ;
Tanaka, S ;
Shimamura, H ;
Aramaki, Y ;
Tsuchiya, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 168 (02) :181-188
[2]
Aleyamma A. J., 1991, BLOOD COMPATIBLE MAT, P123
[3]
Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin [J].
Bhumkar, Devika R. ;
Joshi, Hrushikesh M. ;
Sastry, Murali ;
Pokharkar, Varsha B. .
PHARMACEUTICAL RESEARCH, 2007, 24 (08) :1415-1426
[4]
Chen R, 1998, ADV CHITIN SCI, V3, P16
[5]
NASAL ADMINISTRATION - A TOOL FOR TOMORROWS SYSTEMIC ADMINISTRATION OF DRUGS [J].
DUCHENE, D ;
PONCHEL, G .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1993, 19 (1-2) :101-122
[6]
Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles [J].
Dyer, AM ;
Hinchcliffe, M ;
Watts, P ;
Castile, J ;
Jabbal-Gill, I ;
Nankervis, R ;
Smith, A ;
Illum, L .
PHARMACEUTICAL RESEARCH, 2002, 19 (07) :998-1008
[7]
Enhancement of nasal absorption of insulin using chitosan nanoparticles [J].
Fernández-Urrusuno, R ;
Calvo, P ;
Remuñán-López, C ;
Vila-Jato, JL ;
Alonso, MJ .
PHARMACEUTICAL RESEARCH, 1999, 16 (10) :1576-1581
[8]
Haruta Shunji, 2003, Diabetes Technol Ther, V5, P1, DOI 10.1089/152091503763816409
[9]
Intranasal insulin delivery and therapy [J].
Hinchcliffe, M ;
Illum, L .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 35 (2-3) :199-234
[10]
THE BLOOD COMPATIBILITY OF CHITOSAN AND N-ACYLCHITOSANS [J].
HIRANO, S ;
NOISHIKI, Y .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1985, 19 (04) :413-417